To facilitate harmonized evaluation and comparison of the efficacy of COVID-19 vaccines, study authors proposed a general set of clinical endpoints, along with considerations to guide the selection of primary endpoints.
Patients with asthma who test positive for SARS-CoV-2 may not have a higher risk of hospitalization or severe outcomes associated with COVID-19 compared with patients without asthma.
Researchers indicate that fears of visiting an emergency department because of the pandemic may be unfounded after concluding that SARS-CoV-2 transmission inside an ED is unlikely.
Study authors compared the presentation characteristics and outcomes of adults with and without HIV who were hospitalized with COVID-19.
Earlier this month, shortly after Pfizer announced that its vaccine was 90% effective in preventing COVID-19 in a clinical trial.
In a new study, researchers reported on the frequency of VTE among more than 6000 patients who tested positive for infection with SARS-CoV-2.
Researchers found in an observational cohort study that pre-existing Alzheimer disease and dementia are top risk factors for severe COVID-19 based on their association with positive tests for the coronavirus in England’s hospitals in spring 2020.
The investigational treatment from Regeneron consists of 2 potent, virus-neutralizing antibodies.
Pfizer and BioNTech will submit an Emergency Use Authorization (EUA) request to the FDA for their mRNA-based vaccine candidate BNT162b2 against COVID-19.
Researchers assessed if use of intravenous remdesivir in hospitalized patients with coronavirus disease 2019 infection affected time to recovery and clinical status on days 15 and 29.
